Future Fund LLC Buys 86,584 Shares of ADMA Biologics Inc $ADMA

Future Fund LLC raised its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 88.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 184,016 shares of the biotechnology company’s stock after purchasing an additional 86,584 shares during the period. Future Fund LLC’s holdings in ADMA Biologics were worth $1,658,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC lifted its stake in shares of ADMA Biologics by 3,906.1% in the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after buying an additional 3,838,158 shares during the last quarter. Capital Research Global Investors grew its stake in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Caligan Partners LP acquired a new position in ADMA Biologics in the 3rd quarter valued at $38,653,000. UBS Group AG raised its holdings in ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after acquiring an additional 2,581,670 shares during the period. Finally, Sachem Head Capital Management LP raised its holdings in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares during the period. Institutional investors own 75.68% of the company’s stock.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple plaintiff law firms announced or reiterated the August 10, 2026 deadline for investors to seek lead plaintiff status in the ADMA securities class action, keeping the litigation in focus for shareholders. Article Title
• Neutral Sentiment: Additional notices from firms including Faruqi & Faruqi, Kahn Swick & Foti, Robbins LLP, and Rosen Law Firm reinforce that a class action is already underway, suggesting ongoing legal overhang rather than any operational update. Article Title
• Neutral Sentiment: A Yahoo Finance-linked piece and other commentary reference class actions and probes over revenue allegations, indicating the market is still processing the underlying claims against ADMA Biologics. Article Title

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $8.71 on Friday. The stock has a market cap of $2.02 billion, a P/E ratio of 12.81 and a beta of 0.73. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $20.46. The company has a fifty day moving average price of $8.46 and a 200 day moving average price of $12.28. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.19. The company had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the business posted $0.11 EPS. Analysts anticipate that ADMA Biologics Inc will post 0.8 earnings per share for the current year.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the purchase, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

ADMA has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Mizuho dropped their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective on the stock. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.67.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.